Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

• Status: Completed
• Trial end date: 2005-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Heptavalent Pneumococcal Conjugate Vaccine

Criteria

Inclusion Criteria:

• All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD.

• Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.